Lyell Immunopharma Income Statement (2020-2026) | LYEL

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
0.00M0.01M0.01M12.27M12.36M12.46M12.48M12.48M12.55M12.59M12.70M12.75M12.80M12.83M14.74M14.76M14.83M19.29M17.09M23.33M
Revenue & cost
Revenue (Quarter)
2.63M2.75M2.82M0.55M35.74M0.00M48.39M0.07M0.03M0.03M0.01M0.00M0.01M0.03M0.01M0.01M0.01M0.01M0.01M0.00M
Operating items
Research & Development (Quarter)
46.45M31.43M19.29M35.83M43.72M41.61M38.03M44.63M47.47M43.85M46.99M43.17M40.26M39.50M48.67M43.45M34.86M28.17M52.20M36.60M
Selling, General & Administrative (Quarter)
19.11M21.24M31.87M34.42M30.45M26.08M26.35M19.28M19.03M15.51M13.17M13.49M12.26M11.77M14.52M14.05M9.79M10.69M10.62M9.55M
Other Operating Expenses (Quarter)
0.22M0.76M0.80M1.12M1.17M1.25M1.21M1.29M0.57M0.29M0.64M1.09M0.98M0.73M0.51M0.12M-1.06M1.59M1.50M1.90M
Operating Expenses (Quarter)
65.33M51.92M50.36M69.13M73.00M66.44M63.17M62.62M65.93M59.06M59.52M55.58M51.54M50.54M201.16M57.37M47.15M37.27M127.65M44.26M
Operating Income (Quarter)
-62.71M-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M
EBIT (Quarter)
-62.71M-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M
Non-operating items
Interest & Investment Income (Quarter)
-0.09M-0.14M-1.56M-4.98M-1.75M-1.65M2.40M3.72M1.50M1.20M1.09M-0.31M0.01M1.16M-0.47M-0.13M-0.10M0.14M0.04M-0.25M
Other Non Operating Income (Quarter)
-0.11M0.02M-0.04M0.04M-0.01M-1.07M2.93M1.10M-0.33M1.58M-0.51M1.09M-0.65M-0.04M4.29M1.31M1.18M-4.86M-15.76M17.91M
Non Operating Income (Quarter)
0.11M0.29M0.44M0.40M0.94M-3.82M6.39M4.50M5.26M6.61M6.58M-5.09M6.36M5.92M-3.39M5.17M3.28M-1.59M2.68M2.19M
Net income details
EBT (Quarter)
-173.90M-60.65M-176.32M-175.37M-129.98M-188.38M-192.52M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M
Profit After Tax (Quarter)
-62.59M-48.88M-85.58M-68.14M-36.32M-71.90M-6.00M-66.96M-63.89M-49.66M-52.93M-60.67M-45.81M-43.43M-192.40M-52.20M-42.68M-38.70M-140.77M-24.40M
Income from Continuing Operations (Quarter)
-173.90M-60.65M-176.32M-175.37M-129.98M-188.38M-192.52M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M
Consolidated Net Income (Quarter)
-173.90M-60.65M-176.32M-175.37M-129.98M-188.38M-192.52M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M
Income towards Parent Company (Quarter)
-173.90M-60.65M-176.32M-175.37M-129.98M-188.38M-192.52M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M
Net Income towards Common Stockholders (Quarter)
-173.90M-60.65M-176.32M-175.37M-129.98M-188.38M-192.52M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M
Additional items
EPS (Basic) (Quarter)
-0.08M-0.01M-0.03M-14.36-10.55-15.17-15.58-6.68-7.26-5.57-24.45-5.89-10.14-9.71-42.91-8.73-7.81-5.59-8.47-4.72
EPS (Diluted) (Quarter)
-81.43-5.07-0.03M-14.36-10.55-15.17-15.58-6.68-7.26-5.57-24.45-5.89-10.14-9.71-42.91-8.73-7.81-5.59-8.47-4.72
Shares Outstanding (Quarter)
0.00M0.01M0.01M12.21M12.32M12.42M12.35M12.48M12.51M12.57M12.55M12.71M12.77M12.82M13.07M14.75M14.79M18.27M17.09M21.88M
Shares Outstanding (Diluted) (Quarter)
2.14M11.97M0.01M12.21M12.32M12.42M12.35M12.48M12.51M12.57M12.55M12.71M12.77M12.82M13.07M14.75M14.79M18.27M17.09M21.88M
EBITDA (Quarter)
-62.71M-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M
Interest Expenses (Quarter)
111.11M11.35M127.23M101.82M90.97M120.30M180.13M24.47M26.40M12.21M248.42M19.02M77.96M75.06M359.44M71.38M68.23M65.06M17.09M58.70M